Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FMDY9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $248,762
Award facts
- Contract value 100% obligated
- $248,761.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $248,761.95 to DMS Pharmaceutical Group Inc. for STELARA 90 MG/ML syringes, with an ultimate completion date of December 22, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide.
This delivery order represents one of numerous orders DMS Pharmaceutical Group has received from the Defense Logistics Agency since October 2025 under its prime vendor agreement, which carries a $499,999,999 ceiling value and extends through December 31, 2036. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group supplies an extensive portfolio including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring medical supply needs across military healthcare operations globally. STELARA, an immunosuppressant biologic agent, exemplifies the specialized pharmaceutical products the company provides under this contract vehicle.
Quick answers
Who was awarded contract SPE2DR26FMDY9?
SPE2DR26FMDY9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FMDY9 worth?
The government has obligated $248,762 on SPE2DR26FMDY9.
Is contract SPE2DR26FMDY9 an order under another contract?
Yes. SPE2DR26FMDY9 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDY9 competed?
The extent of competition for SPE2DR26FMDY9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award